Combining radiation and tumor treating fields for advanced pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) in slowing tumor growth in patients with locally advanced pancreatic cancer. Participants will receive SABR therapy once daily for five days and will use the TTF system for at least 18 hours each day starting on the first day of SABR until the tumor progresses or severe side effects occur. The study seeks to determine if this combination approach can improve treatment outcomes for this challenging condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas. Locally advanced pancreas cancer as per National Comprehensive Cancer Network (NCCN) Guidelines.
* Regional lymph node involvement is permitted if able to be treated with radiation therapy.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* At least 3 months of prior FOLFIRINOX, modified FOLFIRINOX, and/or gemcitabine/nab-paclitaxel delivered for pancreas cancer without evidence of distant progression on restaging radiographic studies.
* Carbohydrate antigen 19-9 (CA 19-9) ≤500 U/mL on most recent assessment prior to study enrollment.
* Adequate normal organ and marrow function as defined below:

  i. Hemoglobin ≥8.0 g/dL that may be achieved with transfusion ii. Absolute neutrophil count (ANC) ≥1500 per mm\^3 iii. Platelet count ≥60,000 per mm\^3 iv. Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN) v. AST (SGOT)/ALT (SGPT) ≤3 x institutional ULN
* People of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect they are pregnant while participating in this study, they must inform the treating physician immediately.
* Able to operate the tumor treating field (NovoTTF-100L) system independently or with assistance.
* All participants must sign written informed consent.

Exclusion Criteria:

* Distant metastasis from pancreas cancer.
* Contraindication to having a magnetic resonance imaging (MRI) scan.
* Prior abdominal radiation therapy.
* History of any primary malignancy with the exception of:

  1. Malignancy treated with curative intent and with no known active disease for at least 3 years before enrollment on this study.
  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  3. Adequately treated carcinoma in situ without evidence of disease (i.e., cervical carcinoma in situ; superficial bladder cancer).
* Any unresolved toxicity (Common Terminology Criteria for Adverse Events version 5.0 \> grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to worsen by treatment on this study are permitted to enroll on this study.
* History of inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).
* Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of patient safety or study results.
* Participants who are pregnant or breastfeeding. Patients with an electrical implantable device in the torso. Examples of electrical implanted medical devices include spinal cord stimulators, vagus nerve stimulators, pacemakers, and defibrillators.
* History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse.
* History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.
* Known allergy to medical adhesives or conductive hydrogel \[gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes\].

Where it's running

• Miami Cancer Institute at Baptist Health, Inc.
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Michael Chuong, M.D. — Miami Cancer Institute at Baptist Health, Inc.
• Study coordinator: Michael Chuong, M.D.
• Email: MichaelChu@baptisthealth.net
• Phone: (786) 596-2000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing standard and prolonged chemotherapy before surgery for pancreatic cancer

  This study is testing whether giving longer chemotherapy before surgery can help people with tough-to-treat pancreatic cancer live longer and have better outcomes.

  Recruiting Phase 3 Sahlgrenska University Hospital · Gothenburg, VGR · NCT06714604

• Assessing survival and quality of life in patients with advanced pancreatic cancer

  This study looks at how long people with advanced pancreatic cancer live and how their quality of life is affected while being treated at different hospitals in the Nordic region.

  Recruiting Umeå University · Umeå · NCT05356039

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• INSPIRE: Putting patient-reported info into multidisciplinary tumor boards

  This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama and 2 other locations · NCT07671937

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.